Fidelity Investments’s Trinity Biotech TRIB Stock Holding History

Fidelity Investments’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11	Closed	-$9	–	5565
2025 Q4	$9	Buy	+11	New	+$11	﹤0.01%	5377
2014 Q3	–	Sell	-80,798	Closed	-$9.3M	–	2824
2014 Q2	$9.3M	Sell	80,798 -294,663	-78%	-$34.9M	﹤0.01%	2082
2014 Q1	$45.5M	Sell	375,461 -154,040	-29%	-$20.2M	0.01%	1375
2013 Q4	$66.6M	Buy	529,501 +122,935	+30%	+$14.8M	0.01%	1170
2013 Q3	$44.2M	Sell	406,566 -20,584	-5%	-$2.01M	0.01%	1354
2013 Q2	$36M	Buy	+427,150	New	+$35.4M	0.01%	1401

Other funds holding TRIB

HAIM

Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return

YAG

Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return

Williams & Novak Westlake Village, California $151M AUM 27.43% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

MAWA

Moss Adams Wealth Advisors Seattle, Washington $1.37B AUM 19.97% 1-Year Est. Return

IWA

Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

BCM

Becker Capital Management Portland, Oregon $3.4B AUM 24.68% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments's TRIB Position: Q1 2026 in Review

Fidelity Investments sold out of Trinity Biotech (TRIB) in Q1 2026, closing a stake of 11 shares — an estimated $9 sold.

Fidelity Investments first reported a position in TRIB in Q2 2013 and held it in 6 quarters. The position peaked at $66.6M in Q4 2013. 23 funds tracked by Wall St. Rank hold TRIB as of Q1 2026.

Fidelity Investments reported no remaining Trinity Biotech position as of Q1 2026 after selling out during the quarter.
Fidelity Investments sold 11 Trinity Biotech shares in Q1 2026, an estimated $9.
Fidelity Investments first reported a position in Trinity Biotech in Q2 2013 and held it in 6 quarters.
Fidelity Investments's Trinity Biotech position peaked at $66.6M in Q4 2013.
23 funds tracked by Wall St. Rank held Trinity Biotech as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.